OVID

$2.85+10.47%visit website

Ovid Therapeutics Inc.

Market Cap

$557M

Live price × SEC shares (Aug 11, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.28

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

351.6

TTM to Jun 2026 · revenue

P/B

2.7

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	132	718	0	733	1,583
Research & development	5,870	6,589	11,181	9,957	33,597
Total operating expenses	12,655	13,011	17,846	16,431	59,943
Operating income	(12,523)	(12,293)	(17,846)	(15,698)	(58,360)
Pretax income	(12,158)	9,663	(16,988)	(15,009)	(34,492)
Income tax	0.00	0.00	0.00	0.00	0.00
Net income	(12,158)	9,663	(16,988)	(15,009)	(34,492)

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 13, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 38 more quarters, back to Mar 2016, with Tormere Pro.

Signals

purchases / sales, 90d

Short Volume

47%

W/W +11.1pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-02-23	2026-03-02	ALEXANDER MARGARET A.	Director & President and CEO	Sale	11.7K	$1.45	$17K	61.8K	View
2026-02-23	2026-03-02	Rona Jeffrey A	CBFO	Sale	8,541	$1.45	$12K	88.2K	View